ReviewJournal of endocrinological investigation2020
Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Review in Journal of endocrinological investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Long-term surgical outcomes in TSH-secreting pituitary adenomas: the hidden burden of asymptomatic hyperthyroidism.Endocrine · 2025Article
- miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects.Endocrinology · 2025Article
- New approaches to targeted drug therapy of intracranial tumors.Cell death discovery · 2025Review
- Mutual associations among responsiveness to differential diagnostic tests for Cushing's disease, tumor size, and somatostatin receptor 5 expression in corticotroph tumors.Endocrine journal · 2025Article
- Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective.Brain pathology (Zurich, Switzerland) · 2025Review
- Medical treatment of functional pituitary adenomas, trials and tribulations.Journal of neuro-oncology · 2024Review
- Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2024Review
- Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1.Endocrine connections · 2023Article
- An individualized approach to the management of Cushing disease.Nature reviews. Endocrinology · 2023Review
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.Frontiers in endocrinology · 2023Article
- Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study.European journal of endocrinology · 2022Article
- Aggressive pituitary tumours and pituitary carcinomas.Nature reviews. Endocrinology · 2021Review
- Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Cushing's Syndrome Effects on the Thyroid.International journal of molecular sciences · 2021Review
- Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.Frontiers in endocrinology · 2021Review
- Pasireotide in the Personalized Treatment of Acromegaly.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSomatostatin receptors (SSTs) are widely co-expressed in pituitary tumors. SST
methodsCritical revision of literature data correlating SST expression with patients' response to SRLs.
resultsSST
conclusionsThe assumption "more target receptor, more drug efficacy" is not straightforward for SRLs. The complex pathophysiology of SSTs, and the technical challenges faced to translate research findings into clinical practice, still need our full commitment to make receptor evaluation a worthwhile procedure for individualizing treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.